130 related articles for article (PubMed ID: 36525180)
1. Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: results from the randomized Phase II NeoMET trial.
Huang J; Tong Y; Hong J; Huang O; Wu J; He J; Chen W; Li Y; Chen X; Shen K
Breast Cancer Res Treat; 2023 Feb; 197(3):525-533. PubMed ID: 36525180
[TBL] [Abstract][Full Text] [Related]
2. Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer.
Chen X; Ye G; Zhang C; Li X; Chen Y; Xie X; Zheng H; Cao Y; Wu K; Ni D; Tang J; Wei Z; Shen K
Breast Cancer Res Treat; 2013 Dec; 142(3):549-58. PubMed ID: 24292815
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer.
Li S; Wei W; Jiang Y; Li Q; Huang Q; Yang H; Liu J
Drug Des Devel Ther; 2018; 12():3085-3093. PubMed ID: 30275685
[TBL] [Abstract][Full Text] [Related]
5. Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study.
Chow LW; Tung SY; Ng TY; Im SA; Lee MH; Yip AY; Toi M; Glück S
Expert Opin Investig Drugs; 2013 Mar; 22(3):299-307. PubMed ID: 23394482
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial.
Yang H; Xu L; Guan S; Hao X; Ge Z; Tong F; Cao Y; Liu P; Zhou B; Cheng L; Liu M; Liu H; Xie F; Wang S; Peng Y; Wang C; Wang S
BMC Cancer; 2022 Dec; 22(1):1357. PubMed ID: 36577958
[TBL] [Abstract][Full Text] [Related]
7. Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study.
Ueno T; Masuda N; Sato N; Ohtani S; Yamamura J; Matsunami N; Kashiwaba M; Takano T; Takahashi M; Kaneko K; Ohno S; Morita S; Toi M
Jpn J Clin Oncol; 2020 Jan; 50(1):3-11. PubMed ID: 31821506
[TBL] [Abstract][Full Text] [Related]
8. A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.
Ishiguro H; Masuda N; Sato N; Higaki K; Morimoto T; Yanagita Y; Mizutani M; Ohtani S; Kaneko K; Fujisawa T; Takahashi M; Kadoya T; Matsunami N; Yamamoto Y; Ohno S; Takano T; Morita S; Tanaka-Mizuno S; Toi M
Breast Cancer Res Treat; 2020 Apr; 180(3):715-724. PubMed ID: 32170634
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Therapy with Concurrent Docetaxel, Epirubicin, and Cyclophosphamide (TEC) in High-Risk HER2-Negative Breast Cancers.
Li B; Yau T; Leung R; Kwok G; Tsang J; Cheung P; Wong TT; Suen D; Kwong A; Chiu JW
Adv Ther; 2021 Dec; 38(12):5752-5762. PubMed ID: 34699004
[TBL] [Abstract][Full Text] [Related]
10. UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.
Gonçalves A; Pierga JY; Ferrero JM; Mouret-Reynier MA; Bachelot T; Delva R; Fabbro M; Lerebours F; Lotz JP; Linassier C; Dohollou N; Eymard JC; Leduc B; Lemonnier J; Martin AL; Boher JM; Viens P; Roché H
Ann Oncol; 2015 Aug; 26(8):1692-7. PubMed ID: 25943350
[TBL] [Abstract][Full Text] [Related]
11. Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2
Kuwayama T; Nakamura S; Hayashi N; Takano T; Tsugawa K; Sato T; Kitani A; Okuyama H; Yamauchi H
Clin Breast Cancer; 2018 Dec; 18(6):474-480. PubMed ID: 30072191
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy.
Ohno S; Chow LW; Sato N; Masuda N; Sasano H; Takahashi F; Bando H; Iwata H; Morimoto T; Kamigaki S; Nakayama T; Nakamura S; Kuroi K; Aogi K; Kashiwaba M; Yamashita H; Hisamatsu K; Ito Y; Yamamoto Y; Ueno T; Fakhrejahani E; Yoshida N; Toi M
Breast Cancer Res Treat; 2013 Nov; 142(1):69-80. PubMed ID: 24122389
[TBL] [Abstract][Full Text] [Related]
13. A Randomized Parallel Controlled Phase II Trial of Recombinant Human Endostatin Added to Neoadjuvant Chemotherapy for Stage III Breast Cancer.
Zhang X; Zhang Z; Cao M; Liu B; Mori M; Luoh SW; Bergan R; Liu Y; Liu Y
Clin Breast Cancer; 2020 Aug; 20(4):291-299.e3. PubMed ID: 32482525
[TBL] [Abstract][Full Text] [Related]
14. [Comparative study of chemosensitivity and efficacy between pirarubicin and epirubicin in breast cancer].
Zang MF; Zhang YM; Zhi YH; Zhai Z; Zhang M; Gu F; Zhi XC
Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1388-92. PubMed ID: 21756809
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II trial of adjuvant dose-dense docetaxel/epirubicin/cyclophosphamide (TEC) in stage II and III breast cancer.
Burdette-Radoux S; Wood ME; Olin JJ; Laughlin RS; Crocker AM; Ashikaga T; Muss HB
Breast J; 2007; 13(3):274-80. PubMed ID: 17461902
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study.
Bonnefoi H; Jacot W; Saghatchian M; Moldovan C; Venat-Bouvet L; Zaman K; Matos E; Petit T; Bodmer A; Quenel-Tueux N; Chakiba C; Vuylsteke P; Jerusalem G; Brain E; Tredan O; Messina CG; Slaets L; Cameron D
Ann Oncol; 2015 Feb; 26(2):325-32. PubMed ID: 25467016
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression.
Ando M; Yamauchi H; Aogi K; Shimizu S; Iwata H; Masuda N; Yamamoto N; Inoue K; Ohono S; Kuroi K; Hamano T; Sukigara T; Fujiwara Y
Breast Cancer Res Treat; 2014 Jun; 145(2):401-9. PubMed ID: 24728578
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
[TBL] [Abstract][Full Text] [Related]
19. Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study.
Piedbois P; Serin D; Priou F; Laplaige P; Greget S; Angellier E; Teissier E; Berdah JF; Fabbro M; Valenza B; Herait P; Jehl V; Buyse M
Ann Oncol; 2007 Jan; 18(1):52-57. PubMed ID: 17047001
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
Shimada H; Ueda S; Saeki T; Shigekawa T; Takeuchi H; Hirokawa E; Sugitani I; Sugiyama M; Takahashi T; Matsuura K; Yamane T; Kuji I; Hasebe T; Osaki A
Jpn J Clin Oncol; 2015 Jul; 45(7):642-9. PubMed ID: 25989989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
